Results 141 to 150 of about 848 (155)

Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Galactomannan (GM) detection in biological samples has been shown to predict therapeutic response by azoles and polyenes. In a murine invasive pulmonary aspergillosis model, fosmanogepix or posaconazole treatment resulted in an ∼6- to 7-log reduction in conidial equivalents (CE)/g lung tissue after 96 h versus placebo.
Teclegiorgis Gebremariam, Shakti Singh, Abdullah Alqarihi   +2 more
exaly   +8 more sources

Some of the next articles are maybe not open access.

Related searches:

Fosmanogepix Therapy of Disseminated Fusarium Infection

Clinical Infectious Diseases, 2023
Abstract Invasive Fusarium infections cause high mortality. Fosmanogepix, a first-in-class antifungal agent, has potent activity against Fusarium. A patient with acute leukemia with invasive fusariosis, probably involving the central nervous system and caused by Fusarium lactis resistant to currently available antifungal agents, was ...
Drew J, Winston, Patricia A, Young, Haran T, Schlamm, Gary J, Schiller   +3 more
openaire   +2 more sources

Case Commentary: Long-Term Fosmanogepix Use in a Transplant Recipient with Disseminated Aspergillosis Caused by Azole-Resistant Aspergillus calidoustus

Antimicrobial Agents and Chemotherapy, 2022
Aspergillus calidoustus is an emerging, azole-resistant, cryptic Aspergillus species in immunosuppressed patients that often features extrapulmonary involvement and carries high mortality. The case presented by J.
Michail S Lionakis
exaly   +3 more sources

Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix

Pharmacotherapy
AbstractManagement of invasive fungal infections is challenging with growing antifungal resistance. Broad antifungal use has resulted in greater intrinsic and acquired resistance among Candida spp. It is important for clinicians to recognize the relationship between host susceptibility, site of infection, Candida resistance profiles, specific drug ...
Pramodini B Kale-Pradhan, Benjamin August   +1 more
exaly   +3 more sources

Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants

Antimicrobial Agents and Chemotherapy
ABSTRACT Fosmanogepix [FMGX, APX001; active form: manogepix (MGX), APX001A] is a first-in-class, intravenous (IV)/oral antifungal currently being evaluated for invasive fungal disease treatment. Data from two phase 1, placebo-controlled studies [IV–oral switch (study 1) and multiple IV doses (study 2)] evaluating ...
Margaret Tawadrous, Abhijeet Jakate
exaly   +3 more sources

Fosmanogepix. GPI-anchored wall transfer protein 1 (Gwt1) (fungal) inhibitor, Treatment of invasive fungal infections

Drugs of the Future, 2021
null Thakare, R., null Dasgupta, A., null Chopra, S.   +2 more
openaire   +1 more source

Amphotericin-B-liposomal/fosmanogepix/ondansetron

Reactions Weekly, 2023
openaire   +1 more source

Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model

Antimicrobial Agents and Chemotherapy, 2021
Matthew Zimmerman, Véronique A Dartois, Karen Joy Shaw   +2 more
exaly  

Multi-Drug Resistant Fusariosis Treated with Fosmanogepix in a Lung Transplant Patient

The Journal of Heart and Lung Transplantation
G. Wu, S. Ganesh, K. Forrester, S. Khan
openaire   +1 more source

Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis

Antimicrobial Agents and Chemotherapy, 2019
Nathan P Wiederhold
exaly